Sign inJoin waitlistJoin the waitlist

Mark Shahin

Professor, Department of Obstetrics and Gynecology · Penn State Milton S Hershey Medical Center

Credentials: · · · ·

History

Penn State Milton S Hershey Medical Center
Present

Gynecologic Oncology
2001–2004
University of Iowa Health Care Medical Center
1998–2001
University of Iowa Health Care Medical Center
1997–1998
Obstetrics and Gynecology
Northwestern Memorial Hospital
1993–1997
Feinberg School of Medicine
1989–1993

Research

Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
New England Journal of Medicine · 2019 · 1,824 citations
Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer
New England Journal of Medicine · 2023 · 703 citations
Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer
New England Journal of Medicine · 2023 · 633 citations

Bradley Monk
13 papers
Joel Sorosky
12 papers
Matthew Powell
11 papers
Bhavana Pothuri
9 papers
Floor Backes
9 papers
Lisa Landrum
8 papers
Anil Sood
7 papers
David O'Malley
7 papers
JB
Joseph Buscema
7 papers
RC
Robert Coleman
7 papers
RO
Roisin O'Cearbhaill
7 papers
David Warshal
6 papers

Grants

Sidney Kimmel Cancer Center LAPS Institutional Collaboration
National Cancer Institute · UG1
PI · $2.5M · Thomas Jefferson University
2019–2026

Clinical trials

Seprafilm® for Prevention of Adhesions at Repeat Cesarean
Principal investigator · Terminated · Phase 3
Abington Memorial Hospital
2008–2011
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2026–2028
Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2025–2030
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Site PI · Recruiting
NRG Oncology
2020–2047